OBJECTIVES This study compared serial changes in coronary percent atheroma volume (PAV) and calcium index (CaI) in patients with coronary artery disease who were treated with and without warfarin.
C oronary artery calcification correlates with cardiovascular events (1, 2) . However, emerging evidence increasingly supports the concept that greater calcium density at any level of calcium volume is associated with lower cardiovascular risk (3) . Corroborating these findings, serial coronary intravascular ultrasound (IVUS) examinations revealed the procalcific effects of long-term 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors (statin) therapy despite an association with concomitant atheroma regression, thereby highlighting that plaque delipidation and subsequent calcification could be mechanisms underlying statin-induced plaque stabilization (4) .
Underlying coronary artery calcification is complex pathophysiology involving factors either promoting or inhibiting its process. Matrix Gla protein (MGP) is a vitamin K-dependent protein synthesized by vascular smooth muscle and one of the key inhibitors of the metabolism of coronary artery calcium (5) .
The absence of MGP leads to extensive and lethal medial calcification in mice (6) , and it correlates with arterial calcification in humans (7, 8) . Warfarin blocks the synthesis and activity of MGP by reducing gamma-carboxylation of vascular MGP (5) . However, the impact of warfarin on serial coronary artery calcification in humans in vivo is currently unknown.
Serial coronary IVUS has been pivotal in elucidating factors promoting coronary atheroma progression and regression (9) , as well as their relationships with clinical events (10, 11) . Measuring plaque calcification and atheroma volume with the high imaging resolution of coronary IVUS is well described and validated (12) . In patients with coronary artery disease, we tested the hypothesis that serial changes in coronary artery calcium are greater in warfarin-treated patients compared with patients not receiving warfarin, independent of changes in coronary plaque volume.
METHODS STUDY POPULATION. The present analysis included patients participating in 8 clinical trials that used IVUS to assess the impact of medical therapies on serial changes in coronary atheroma burden (Online Table 1 were traced by manual planimetry. Plaque area was defined as the area occupied between these leading edges. The accuracy and reproducibility of this method were reported previously (22) . The percent atheroma volume (PAV) was determined by calculating the proportion of the entire vessel wall occupied by atherosclerotic plaque throughout the segment of interest, as follows: Warfarin and Coronary Artery Calcification -2 0 were estimated by a generalized linear model, using all the confounders detected for warfarin use versus change in CaI ranks as covariates (see Online Figure 1 for the list of confounders for IPTW on CaI). The balance of the pre-treatment covariates was assessed by checking absolute standardized differences in baseline confounders between concomitant warfarin use and non-warfarin use before and after IPTW adjustment, and significant improvement in baseline balance was achieved following weighting, as judged by a 10% threshold (Online Figure 1 for IPTW on CaI).
IPTW on PAV shared the same covariate set and therefore had the same magnitude of weighting. Warfarin and Coronary Artery Calcification -2 0 
Non-HDL-C
Median of % change À17.0 (À17.9 to À16.1) À19.1 (À24.0 to À14.2) À17.0 (À18.0 to À16.0) 0.88 p value ‡ -<0.001 <0.001 -
Triglycerides
Median of % change À7.2 (À8.2 to À6.2) À9.7 (À14.5 to À4.9) À7.1 (À8.1 to À6.1) 0.35 p value ‡ -0.006 <0.001 -
CRP
Median of % change À22.4 (À24.9 to À19.9) À14.8 (À27.3 to À2.3) À22.6 (À25.1 to À20.1) 0.80 p value ‡ -0.28 <0.001 -
Creatinine
Median of % change 0.0 (À0.5 to 0.5) 0.0 (À2.7 to 2.7) 0.0 (À0.5 to 0.5) 0.006 p value ‡ <0.001 0.12 <0.001 -Values are mean AE SD or median (95% CI). The 95% CIs of the medians are calculated using the formula 95% CImedian A further sensitivity (trimmed) analysis that removed patients with a propensity score >0.1 or z5% of the total study population did not yield data that significantly differed from those of the principal analysis (Online Tables 2 and 3 ). Abbreviations as in Tables 1 to 3 .
DISCUSSION
Andrews et al. Our data are thus consistent with, and extend the findings of, prior imaging studies undertaken to evaluate the effects of warfarin on the human arterial vasculature (28) (29) (30) . However, these prior analyses were limited by their cross-sectional design and by the issues that concomitant plaque volume measurements were not undertaken and relatively low numbers of patients were evaluated at a single time point. Nevertheless, the association between warfarin use and its procalcific properties has been demonstrated in multiple arterial territories in humans. In 1 cohort study, the presence of lower extremity arterial calcification was greater in patients exposed to warfarin compared with those not exposed to the drug (29) . Other human imaging studies have also demonstrated the association between warfarin exposure and calcification involving the femoral (29) and breast (30) more extended period of warfarin therapy. The current analysis was not a placebo-controlled trial.
However, it is highly unlikely that there will ever be such a trial because it is unethical to administer (or withhold) warfarin simply to evaluate its effects on Warfarin and Coronary Artery Calcification -2 0 1 7 : ---
